Suppr超能文献

预防早产和管理早产临产的新药专家共识:目标产品特征。

Expert consensus on novel medicines to prevent preterm birth and manage preterm labour: Target product profiles.

机构信息

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Victoria, Australia.

Policy Cures Research, Sydney, New South Wales, Australia.

出版信息

BJOG. 2024 Jan;131(1):71-80. doi: 10.1111/1471-0528.17314. Epub 2022 Oct 27.

Abstract

OBJECTIVE

To develop target product profiles (TPPs) for new medicines for preterm birth prevention and preterm labour management that address the real-world need of women and healthcare providers, informed by views and agreement amongst globally diverse stakeholders.

DESIGN

Mixed methods.

SETTING

Global (with a focus on low- and middle-income countries, LMICs).

SAMPLE

Global stakeholders with diverse expertise in preterm labour/birth and drug development.

METHODS

Following an initial literature review, diverse stakeholders were invited to participate in an online international survey and in-depth interviews. The level of stakeholder agreement with TPPs was assessed, and findings from interviews were synthesised to inform the final TPPs.

MAIN OUTCOMES MEASURES

Level of stakeholder agreement on the minimum and preferred requirements for preterm labour/birth medicines.

RESULTS

We performed 21 interviews. Interview participants demonstrated strong agreement on room temperature stability, no additional drug-specific clinical monitoring, and affordability in LMICs being the minimal acceptable requirements. Points of discussion were raised around the target population. Survey respondents included clinicians, researchers, funding agency staff, international public organisation staff, programme implementers, policymakers, representatives of consumer advocacy organisations and other relevant stakeholders from maternal health systems. Survey results indicated strong agreement amongst stakeholders, with only one variable in each TPP not reaching consensus (i.e. 25% disagree or strongly disagree).

CONCLUSIONS

There is strong consensus within the preterm labour/birth community on the characteristics that new medicines for preterm birth prevention and preterm labour management must achieve. These TPPs provide necessary guidance to evaluate new candidates and their potential for implementation in a range of settings.

摘要

目的

针对预防早产和早产临产的新药制定目标产品概况(TPP),以满足女性和医疗保健提供者的实际需求,并在全球不同利益相关者的观点和共识的基础上进行。

设计

混合方法。

设置

全球(重点关注低收入和中等收入国家,LMICs)。

样本

在早产/分娩和药物开发方面具有不同专业知识的全球利益相关者。

方法

在初步文献综述之后,邀请不同的利益相关者参与在线国际调查和深入访谈。评估了利益相关者对 TPP 的一致程度,并综合了访谈结果以提供最终的 TPP。

主要结果测量

利益相关者对早产/分娩药物最低和首选要求的一致程度。

结果

我们进行了 21 次访谈。访谈参与者对室温稳定性、无需额外的药物特异性临床监测以及在 LMICs 中的可负担性表现出强烈的一致,认为这是可接受的最低要求。对于目标人群存在一些讨论点。调查参与者包括临床医生、研究人员、资金机构工作人员、国际公共组织工作人员、方案实施者、政策制定者、消费者权益组织代表和其他来自孕产妇保健系统的相关利益相关者。调查结果表明,利益相关者之间存在强烈的一致,每个 TPP 中只有一个变量未达成共识(即 25%的人不同意或强烈不同意)。

结论

在早产/分娩领域,对于预防早产和早产临产的新药,必须达到哪些特征,存在着强烈的共识。这些 TPP 为评估新候选药物及其在各种环境中的实施潜力提供了必要的指导。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验